Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.23 - $160.0 $117,917 - $82 Million
-512,685 Reduced 72.76%
191,939 $33,000
Q2 2022

Aug 15, 2022

BUY
$0.23 - $0.46 $114,588 - $229,177
498,211 Added 241.37%
704,624 $186,000
Q1 2022

May 16, 2022

SELL
$0.3 - $0.61 $35,268 - $71,712
-117,562 Reduced 36.29%
206,413 $88,000
Q4 2021

Feb 14, 2022

BUY
$0.55 - $1.04 $133,602 - $252,629
242,913 Added 299.66%
323,975 $178,000
Q3 2021

Nov 15, 2021

BUY
$1.06 - $1.52 $60,087 - $86,162
56,686 Added 232.55%
81,062 $86,000
Q2 2021

Aug 16, 2021

SELL
$1.22 - $1.65 $33,791 - $45,701
-27,698 Reduced 53.19%
24,376 $36,000
Q1 2021

May 17, 2021

BUY
$1.18 - $2.62 $61,447 - $136,433
52,074 New
52,074 $80,000
Q1 2020

May 15, 2020

SELL
$0.22 - $2.45 $25,936 - $288,832
-117,891 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.11 - $0.58 $6,705 - $35,354
60,956 Added 107.06%
117,891 $29,000
Q2 2019

Aug 14, 2019

BUY
$0.71 - $0.91 $2,622 - $3,361
3,694 Added 6.94%
56,935 $40,000
Q1 2019

May 15, 2019

BUY
$0.75 - $1.0 $19,992 - $26,656
26,656 Added 100.27%
53,241 $0
Q4 2018

Feb 14, 2019

BUY
$0.57 - $1.05 $15,153 - $27,914
26,585 New
26,585 $19,000

About iBio, Inc.


  • Ticker IBIO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,006,580
  • Market Cap $24M
  • Description
  • iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for t...
More about IBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.